Abstract
Genetics researchers and clinical professionals rely on diversity measures such as race, ethnicity, and ancestry (REA) to stratify study participants and patients for a variety of applications in research and precision medicine. However, there are no comprehensive, widely accepted standards or guidelines for collecting and using such data in either setting. Two NIH-funded research consortia, the Clinical Genome Resource (ClinGen) and Clinical Sequencing Evidence-generating Research (CSER), partnered to survey 448 clinical genetics professionals and researchers. The study found significant heterogeneity in how REA are perceived, defined, and measured. While the majority of respondents (>55%) viewed REA as important for clinical variant interpretation and genetic testing, there was no consensus on how these measures should be used or what specific information they convey. These findings highlight an urgent need for the standardization and harmonization of REA data collection to prevent inconsistencies in data collection and inaccurate clinical classifications.
Introduction
In the era of precision medicine, a patient’s background is a critical variable in the interpretation of genetic data. A variant that appears rare and potentially pathogenic in one population may be common and benign in another. To navigate this, clinicians and researchers frequently employ measures of diversity: Race, Ethnicity, and Ancestry (REA). However, the field currently lacks a unified framework for these concepts.
While race and ethnicity are largely socio-cultural constructs reflecting identity and environmental exposures, ancestry refers to the biological inheritance of genetic variants. In practice, these terms are often conflated or used interchangeably. This lack of a "common tongue" can lead to inaccurate variant classifications, misleading clinical reports, and the potential exacerbation of existing health disparities. This study investigates how genetics professionals conceptualize and apply these measures in clinical and research settings.
Methodology
The study utilized a cross-sectional survey design developed through a partnership between two NIH-funded consortia: the Clinical Genome Resource (ClinGen) and Clinical Sequencing Evidence-generating Research (CSER).
The survey instrument consisted of 121 questions. To ensure robustness, the authors conducted 11 "cognitive interviews" with target professionals to refine the language and logic before full deployment. Recruitment was conducted via professional organizations—such as the American College of Medical Genetics and Genomics (ACMG) and the American Society of Human Genetics (ASHG)—and various listservs, utilizing a "snowball" sampling approach.
Data from 448 respondents were analyzed using descriptive statistics. The survey employed branching logic to tailor questions to specific professional roles, including laboratory directors, genetic counselors, and non-clinical researchers.
Participant Demographics
The cohort of 448 respondents was composed of:
- Clinical Professionals (60%): Including geneticists, genetic counselors, and laboratory directors.
- Non-clinical Researchers (22%): Focused on human genetics and genomics.
- Trainees and Others (18%): Representing the next generation of the field.
The sample was predominantly North American (93%) and majority-white (71%). While the authors acknowledge this as a limitation, they note it is reflective of the current demographics of the genetics profession in the United States.
Key Insights
The Ancestry Disconnect
One of the most striking findings was the gap between theoretical importance and clinical practice regarding ancestry. While 66% of respondents agreed that "genetic lineage group" best describes ancestry, and ancestry was rated as the most critical factor for variant interpretation, 85% of respondents reported that genetic ancestry is rarely or never actually calculated from a patient’s DNA in a clinical setting.
Proxies by Necessity
Because quantitative genetic ancestry data is rarely available, clinicians frequently rely on self-reported race or information found in medical records as a proxy. The authors emphasize that this is scientifically problematic, particularly for individuals with multi-ancestral backgrounds, as socio-cultural identity does not always align with genetic lineage.
Heterogeneity of Thought and Uncertainty
The survey revealed no single definition for "race" that achieved a majority consensus. Furthermore, professionals expressed higher confidence in distinguishing between REA terms in "genetics-specific" contexts than in "general" contexts. This suggests a functional, albeit potentially superficial, understanding of these terms within the workplace.
For many clinical scenarios, up to a third of respondents answered "I'm not sure" or "It depends" regarding the relevance of REA. This high degree of uncertainty underscores the difficulty of applying diversity measures to individual patient care without clear protocols.
Clinical Motivations and Results
The survey highlighted several key trends in how REA data is currently utilized:
- Widespread Use: 94% of participants collect or use population identity information in their work.
- Clinical Triggers: 53% of professionals are more likely to discuss REA if the patient is from a racial or ethnic minority group.
- Variant Interpretation: 50% are motivated to investigate REA more deeply when faced with a Variant of Uncertain Significance (VUS).
- Demand for Reform: 65% of respondents explicitly stated that new, standardized guidelines for the collection and use of REA data are necessary for the field.
Limitations and Future Directions
The study’s primary limitation is its geographic and demographic bias toward white, North American professionals. This may not capture the perspectives of professionals in more diverse global regions or those working in different healthcare systems. Additionally, the "snowball" recruitment method prevents the calculation of a precise response rate.
The authors conclude that a multi-disciplinary effort is required to move the field forward. This should involve stakeholders from clinical laboratories, professional organizations, and patient advocacy groups to develop a formal framework. Such a framework must prioritize the use of validated genetic ancestry alongside socio-cultural data, ensuring that precision medicine is both scientifically accurate and equitably applied.
Summary updated